Unleashing the power of silence: investigating the epigenetic silencer hush as a new target for treating acute myeloid leukemia

The federal Project Grant award of $108,940.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to support the research project "UNLEASHING THE POWER OF SILENCE: INVESTIGATING THE EPIGENETIC SILENCER HUSH AS A NEW TARGET FOR TREATING ACUTE MYELOID LEUKEMIA." The award was granted to the foreign-owned, non-profit Walter and Eliza Hall Institute of Medical Research in Australia, with a performance period from December 1, 2024 to November 30, 2026. The project aims to investigate the epigenetic silencer HUSH as a potential new target for treating acute myeloid leukemia, leveraging the institute's expertise in complex medical research across areas like cancer, immunology, and genomics. The award demonstrates the Defense Health Agency's commitment to funding innovative biomedical research initiatives with the potential to transform healthcare for military service members and the broader public.